Replies to post #342011 on Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

Link?

[Hungry_Ghost]

Nice FACTUAL NEWS. THANKS. BRILACIDIN *426*

[BeingReal]

What was the date of this quote?

EDit...I just found it in my email, Dec 21, 2020.

[LilyGDog]

Awesome post, very well done!

Go Leo & IPIX!

BRILACIDIN: FDA clears a Phase 2 clinical trial on Covid-19 of an HDP mimetic.
…………………….
Antibiotic / antiviral / anti-inflammatory, this drug has been selected from over 11,500 compounds to inhibit SARS-CoV-2 proliferation by up to 97% with a selectivity index of 426.
………………………… ..
After Remdesivir , Desmetasone and other drugs "fished out" (drug repurposing) in contrast to SARS-CoV-2, from the United States comes the announcement of an eighth compound with a very promising result. The announcement came a few days ago, by Innovation Pharmaceuticals, a company that is studying Brilacidin in Covid-19. Drug that in July 2019 was the subject of an agreement with Alfasigma, an Italian pharmaceutical company, in the treatment of Ulcerative Proctitis and Ulcerative Proctosigmoiditis.
Brilacidin would also be active in the "new" variants of the coronavirus, the English, Danish and South African variants. And, more generally, it would be effective as a pan-coronavirus. The "international" study will involve 120 hospitalized Covid-19 patients.
……………………… ..
In vitro active on all variants

In in vitro studies, Brilacidin was found to be a potent inhibitor of all variants of SARS-CoV-2, from the Washington to the Italian, from the English to the Danish and South African variants. Another interesting fact, which emerged from the preclinical study, is the effectiveness of Brilacidin on other coronaviruses that infect humans, in addition to SARS-CoV-2, such that it can be defined as a "pan-coronavirus" drug.

Tested on a human lung cell line (Calu-3) and a monkey cell (Vero), Brilacidin inhibited the proliferation of the novel coronavirus (COVID-19) by up to 97%, even at the lowest concentrations evaluated so far.

Clinical trial begins

These results allowed the FDA to clear a Phase 2 clinical trial of Brilacidin. Drug previously studied in the clinic (on over 460 subjects) for other indications. Now it has been "fished out" thanks to a molecular screening, on 11,552 compounds, where it was found capable of selectively targeting Covid-19 with a selectivity of 426.

The clinical study also bodes well on the basis of the results of in vitro tests, conducted at independent laboratories, where Brilacidin in addition to the already known anti-inflammatory properties (inhibition of IL-6, IL-1ß, TNF-a and other cytokines and chemokines inflammatory) and antibacterial, it was found to be a potent antiviral - capable of inhibiting SARS-CoV-2 and other human coronavirus (H-CoV) strains.

The results of this study were published in BioRxiv, first author Allison Bakovic.

A particularly interesting pharmacological profile, from a clinical point of view, given that Covid-19 patients are attacked by a very violent inflammatory process and that, in 20% of cases, they also develop secondary bacterial infections. Finally, the data on the inhibition of other coronaviruses (potential pan-coronavirus) is not negligible.

The clinical study will engage several international experimental centers, starting with the United States. 120 hospitalized Covid-19 patients will be enrolled. The primary endpoint of the study is to evaluate the recovery of Covid-19 patients, assessed on the 29th day.

A second possibility is the combination of Brilacidin with Remdesivir, the first drug (from Gilead Sciences) approved by the FDA against Covid-19, and always selected with the drug repurposing (or drug repositioning) approach. In in vitro tests, these two molecules showed synergistic action against SARS-CoV-2.

An HDP camouflage

Brilacidin is an antibiotic that works by breaking down bacterial cell membranes, mimicking the defensins that play a role in innate immunity. Several imitations of antimicrobial peptides, both peptides and non-peptides, have been studied, but none have reached the market so far.

In a Phase 2 clinical trial (Topline study), as an oral rinse, Brilacidin was able to alleviate oral mucositis in head and neck cancer patients undergoing chemo-radiotherapy.

Growing evidence shows that antimicrobial peptides (AMPs), both natural and synthetic, also known as antimicrobial peptides or defensins, or even Host Defense Proteins / Peptides (HDP), can inhibit SARS-CoV-2 and find a possible clinical application for this. purpose. Brilacidin is a synthetic molecule and belongs precisely to the class of HDP mimetics.

In July 2019, Brilacidin was the subject of an agreement entered into between the US Biotech Innovation Pharmaceuticals and the Italian multinational pharmaceutical company Alfasigma which acquired the rights globally for the commercialization in the treatment of Proctitis Ulcerosa (PU) and Proctosigmoiditis Ulcerosa (PSU) . Proctitis is an inflammatory disease of the rectum which, when it also extends to the sigma, is called Proctosigmoiditis.
PU and PSU are Chronic Inflammatory Bowel Diseases (IBD) which include Crohn's disease and ulcerative colitis

[unstable genious 1]

Thankyou for sharing this with the group Dude...:)...love it

[steelyeye]

Nice summary and important to highlight a few things:

BRILACIDIN: FDA clears a Phase 2 clinical trial on Covid-19 of an HDP mimetic.
…………………….
Antibiotic / antiviral / anti-inflammatory, this drug has been selected from over 11,500 compounds to inhibit SARS-CoV-2 proliferation by up to 97% with a selectivity index of 426.
………………………… ..
After Remdesivir , Desmetasone and other drugs "fished out" (drug repurposing) in contrast to SARS-CoV-2, from the United States comes the announcement of an eighth compound with a very promising result. The announcement came a few days ago, by Innovation Pharmaceuticals, a company that is studying Brilacidin in Covid-19. Drug that in July 2019 was the subject of an agreement with Alfasigma, an Italian pharmaceutical company, in the treatment of Ulcerative Proctitis and Ulcerative Proctosigmoiditis.
Brilacidin would also be active in the "new" variants of the coronavirus, the English, Danish and South African variants. And, more generally, it would be effective as a pan-coronavirus. The "international" study will involve 120 hospitalized Covid-19 patients.
……………………… ..
In vitro active on all variants

In in vitro studies, Brilacidin was found to be a potent inhibitor of all variants of SARS-CoV-2, from the Washington to the Italian, from the English to the Danish and South African variants. Another interesting fact, which emerged from the preclinical study, is the effectiveness of Brilacidin on other coronaviruses that infect humans, in addition to SARS-CoV-2, such that it can be defined as a "pan-coronavirus" drug.

Tested on a human lung cell line (Calu-3) and a monkey cell (Vero), Brilacidin inhibited the proliferation of the novel coronavirus (COVID-19) by up to 97%, even at the lowest concentrations evaluated so far.

Clinical trial begins

These results allowed the FDA to clear a Phase 2 clinical trial of Brilacidin. Drug previously studied in the clinic (on over 460 subjects) for other indications. Now it has been "fished out" thanks to a molecular screening, on 11,552 compounds, where it was found capable of selectively targeting Covid-19 with a selectivity of 426.

The clinical study also bodes well on the basis of the results of in vitro tests, conducted at independent laboratories, where Brilacidin in addition to the already known anti-inflammatory properties (inhibition of IL-6, IL-1ß, TNF-a and other cytokines and chemokines inflammatory) and antibacterial, it was found to be a potent antiviral - capable of inhibiting SARS-CoV-2 and other human coronavirus (H-CoV) strains.

The results of this study were published in BioRxiv, first author Allison Bakovic.

A particularly interesting pharmacological profile, from a clinical point of view, given that Covid-19 patients are attacked by a very violent inflammatory process and that, in 20% of cases, they also develop secondary bacterial infections. Finally, the data on the inhibition of other coronaviruses (potential pan-coronavirus) is not negligible.

The clinical study will engage several international experimental centers, starting with the United States. 120 hospitalized Covid-19 patients will be enrolled. The primary endpoint of the study is to evaluate the recovery of Covid-19 patients, assessed on the 29th day.

A second possibility is the combination of Brilacidin with Remdesivir, the first drug (from Gilead Sciences) approved by the FDA against Covid-19, and always selected with the drug repurposing (or drug repositioning) approach. In in vitro tests, these two molecules showed synergistic action against SARS-CoV-2.

An HDP camouflage

Brilacidin is an antibiotic that works by breaking down bacterial cell membranes, mimicking the defensins that play a role in innate immunity. Several imitations of antimicrobial peptides, both peptides and non-peptides, have been studied, but none have reached the market so far.

In a Phase 2 clinical trial (Topline study), as an oral rinse, Brilacidin was able to alleviate oral mucositis in head and neck cancer patients undergoing chemo-radiotherapy.

Growing evidence shows that antimicrobial peptides (AMPs), both natural and synthetic, also known as antimicrobial peptides or defensins, or even Host Defense Proteins / Peptides (HDP), can inhibit SARS-CoV-2 and find a possible clinical application for this. purpose. Brilacidin is a synthetic molecule and belongs precisely to the class of HDP mimetics.

In July 2019, Brilacidin was the subject of an agreement entered into between the US Biotech Innovation Pharmaceuticals and the Italian multinational pharmaceutical company Alfasigma which acquired the rights globally for the commercialization in the treatment of Proctitis Ulcerosa (PU) and Proctosigmoiditis Ulcerosa (PSU) . Proctitis is an inflammatory disease of the rectum which, when it also extends to the sigma, is called Proctosigmoiditis.
PU and PSU are Chronic Inflammatory Bowel Diseases (IBD) which include Crohn's disease and ulcerative colitis